Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity

BACKGROUND: Mirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Invest
Hoofdauteurs: O’Mara, Alana E., Johnson, James W., Linderman, Joyce D., Brychta, Robert J., McGehee, Suzanne, Fletcher, Laura A., Fink, Yael A., Kapuria, Devika, Cassimatis, Thomas M., Kelsey, Nathan, Cero, Cheryl, Sater, Zahraa Abdul, Piccinini, Francesca, Baskin, Alison S., Leitner, Brooks P., Cai, Hongyi, Millo, Corina M., Dieckmann, William, Walter, Mary, Javitt, Norman B., Rotman, Yaron, Walter, Peter J., Ader, Marilyn, Bergman, Richard N., Herscovitch, Peter, Chen, Kong Y., Cypess, Aaron M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Clinical Investigation 2020
Onderwerpen:
Clinical Medicine
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7190915/
https://ncbi.nlm.nih.gov/pubmed/31961826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI131126
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items